TPIV200/huFR-1
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for TPIV200/huFR-1, covering 2021-11-30 to 2021-11-30. Get the full timeline:
Most recent: Clinical Trial Update: TPIV200/huFR-1 (A Multi-Epitope Anti-Folate Receptor Vaccine) Plus Anti-PD-L1 MEDI4736 (Durvalumab) in Patients With Platinum Resistant Ovarian Cancer [Phase 2]